Cargando…

The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study

Background  Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic options for medical and surgical oncology patients presenting to h...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsheef, Mohammed, Bazarbashi, Shouki, Warsi, Ashraf, Alfraih, Feras, Almoomen, Abdualkreem, Osman, Ahmed, Owaidah, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825204/
https://www.ncbi.nlm.nih.gov/pubmed/36751300
http://dx.doi.org/10.1055/s-0042-1758856
_version_ 1784866587532066816
author Alsheef, Mohammed
Bazarbashi, Shouki
Warsi, Ashraf
Alfraih, Feras
Almoomen, Abdualkreem
Osman, Ahmed
Owaidah, Tarek
author_facet Alsheef, Mohammed
Bazarbashi, Shouki
Warsi, Ashraf
Alfraih, Feras
Almoomen, Abdualkreem
Osman, Ahmed
Owaidah, Tarek
author_sort Alsheef, Mohammed
collection PubMed
description Background  Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic options for medical and surgical oncology patients presenting to health care settings in Saudi Arabia. Methods  The present consensus was developed in concordance with the modified Delphi-based approach, which incorporates a face-to-face meeting between two voting rounds to gain experts' feedback on the proposed statements. All experts were either oncologists, hematologists, or hemato-oncologist with an active clinical and research profile in hemato-oncology. Results  The experts highlighted that the comparatively high incidence of inherited thrombophilia among the Saudi population may account for a higher CT burden in the Kingdom than in other parts of the world. However, due to the lack of literature that assesses CT in Saudi Arabia, primary venous thromboembolism prophylaxis should be tailored according to a valid risk assessment of cancer patients and should be implemented in routine practice. For hospitalized medical oncology patients, the experts agreed that prophylaxis with low-molecular-weight heparin (LMWH) should be offered, regardless of the presence of acute illness. For ambulatory medical oncology patients, LMWH or direct oral anticoagulants (DOACs) prophylaxis should be offered for high-risk patients. Concerning surgical patients, they agreed that all oncology patients undergoing surgery should be offered thromboprophylaxis. In terms of secondary prophylaxis, the experts recommended continuing a prophylactic dose of anticoagulant (LMWH or DOAC), for an appropriate period depending on the cancer type and stage. Finally, they also provided a set of statements on management of CT in Saudi Arabia. Conclusion  The present modified Delphi-based study combined the best available evidence and clinical experience with the current health care policies and settings in Saudi Arabia to build a consensus statement on the epidemiology, prevention, and management of CT.
format Online
Article
Text
id pubmed-9825204
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-98252042023-02-06 The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study Alsheef, Mohammed Bazarbashi, Shouki Warsi, Ashraf Alfraih, Feras Almoomen, Abdualkreem Osman, Ahmed Owaidah, Tarek TH Open Background  Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic options for medical and surgical oncology patients presenting to health care settings in Saudi Arabia. Methods  The present consensus was developed in concordance with the modified Delphi-based approach, which incorporates a face-to-face meeting between two voting rounds to gain experts' feedback on the proposed statements. All experts were either oncologists, hematologists, or hemato-oncologist with an active clinical and research profile in hemato-oncology. Results  The experts highlighted that the comparatively high incidence of inherited thrombophilia among the Saudi population may account for a higher CT burden in the Kingdom than in other parts of the world. However, due to the lack of literature that assesses CT in Saudi Arabia, primary venous thromboembolism prophylaxis should be tailored according to a valid risk assessment of cancer patients and should be implemented in routine practice. For hospitalized medical oncology patients, the experts agreed that prophylaxis with low-molecular-weight heparin (LMWH) should be offered, regardless of the presence of acute illness. For ambulatory medical oncology patients, LMWH or direct oral anticoagulants (DOACs) prophylaxis should be offered for high-risk patients. Concerning surgical patients, they agreed that all oncology patients undergoing surgery should be offered thromboprophylaxis. In terms of secondary prophylaxis, the experts recommended continuing a prophylactic dose of anticoagulant (LMWH or DOAC), for an appropriate period depending on the cancer type and stage. Finally, they also provided a set of statements on management of CT in Saudi Arabia. Conclusion  The present modified Delphi-based study combined the best available evidence and clinical experience with the current health care policies and settings in Saudi Arabia to build a consensus statement on the epidemiology, prevention, and management of CT. Georg Thieme Verlag KG 2023-01-07 /pmc/articles/PMC9825204/ /pubmed/36751300 http://dx.doi.org/10.1055/s-0042-1758856 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Alsheef, Mohammed
Bazarbashi, Shouki
Warsi, Ashraf
Alfraih, Feras
Almoomen, Abdualkreem
Osman, Ahmed
Owaidah, Tarek
The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study
title The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study
title_full The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study
title_fullStr The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study
title_full_unstemmed The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study
title_short The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study
title_sort saudi consensus for the management of cancer-associated thromboembolism: a modified delphi-based study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825204/
https://www.ncbi.nlm.nih.gov/pubmed/36751300
http://dx.doi.org/10.1055/s-0042-1758856
work_keys_str_mv AT alsheefmohammed thesaudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT bazarbashishouki thesaudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT warsiashraf thesaudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT alfraihferas thesaudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT almoomenabdualkreem thesaudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT osmanahmed thesaudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT owaidahtarek thesaudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT alsheefmohammed saudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT bazarbashishouki saudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT warsiashraf saudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT alfraihferas saudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT almoomenabdualkreem saudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT osmanahmed saudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy
AT owaidahtarek saudiconsensusforthemanagementofcancerassociatedthromboembolismamodifieddelphibasedstudy